Sectors

FATE
Fate Therapeutics, Inc.
2.53
2 x 1.91
2 x 3.28
bid
ask
+
0.01
0.40%
2 @ 07:30 PM
2.53 +0.00 (0.00%)
Ytd158.16%
1y153.00%
2.48
day range
2.61
0.96
52 week range
3.11
Open2.56Prev Close2.52Low2.48High2.61Mkt Cap303.15M
Vol4.19MAvg Vol2.72MEPS-1.05P/EN/AForward P/E-0.99
Beta1.88Short Ratio3.10Inst. Own102.25%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-1250-d Avg2.57200-d Avg1.781yr Est6.31
Income Statement
Total Revenue2.08M
Revenues (USD)2.08M
Gross Profit2.08M
Operating Expenses33.22M
Research and Development Expense24.39M
Selling, General and Administrative Expense8.83M
Operating Income-31.13M
Net Income-30.16M
Net Income Common Stock-30.16M
Net Income Common Stock (USD)-30.16M
Consolidated Income-30.16M
Earnings per Basic Share-0.25
Earnings per Basic Share (USD)-0.25
Earnings per Diluted Share-0.25
Earning Before Interest & Taxes (EBIT)-30.16M
Earning Before Interest & Taxes (USD)-30.16M
Weighted Average Shares120.40M
Weighted Average Shares Diluted120.40M
Balance Sheet
Cash and Equivalents42.48M
Cash and Equivalents (USD)42.48M
Investments121.34M
Investments Current121.34M
Trade and Non-Trade Receivables703.00K
Current Assets157.95M
Property, Plant & Equipment Net92.10M
Total Assets260.10M
Debt Current4.92M
Total Debt75.68M
Current Liabilities32.59M
Debt Non-Current70.75M
Total Liabilities106.67M
Accumulated Retained Earnings (Deficit)-1.60B
Accumulated Other Comprehensive Income-117.00K
Shareholders Equity153.44M
Shareholders Equity (USD)153.44M
Assets Non-Current102.15M
Total Debt (USD)75.68M
Liabilities Non-Current74.07M
Trade and Non-Trade Payables3.26M
Cash Flow
Depreciation, Amortization & Accretion2.78M
Net Cash Flow / Change in Cash & Cash Equivalents-7.14M
Capital Expenditure-80.00K
Net Cash Flow from Investing14.56M
Net Cash Flow - Investment Acquisitions and Disposals14.64M
Net Cash Flow from Operations-23.43M
Share Based Compensation3.52M